Chronic kidney disease (CKD) is the leading complication in type 2 diabetes (T2D) and
current therapies that limit CKD progression and the development of cardiovascular disease …

Traditional dietary recommendations for patients with chronic kidney disease (CKD) focus
on the quantity of nutrients consumed. Without appropriate dietary counselling, these …

Background: Hyperkalemia increases risk of cardiac arrhythmias and death and limits the
use of renin-angiotensin-aldosterone system inhibitors and mineralocorticoid receptor …

This is an opportune time to publish the first KDIGO 2020 Clinical Practice Guideline for
Diabetes Management in Chronic Kidney Disease (CKD). Worldwide, the estimated number …

Hyperkalemia is an electrolyte abnormality with potentially life-threatening consequences.
Despite various guidelines, no universally accepted consensus exists on best practices for …

The original KDIGO Clinical Practice Guideline for the Management of Blood Pressure in
Chronic Kidney Disease in the chronic kidney disease (CKD) population not receiving …

Background Epidemiologic studies, including trials, suggest an association between
potassium intake and blood pressure (BP). However, the strength and shape of this …

Aims Hyperkalaemia is a common complication of type 2 diabetes mellitus (T2DM) and limits
the optimal use of agents that block the renin–angiotensin–aldosterone system, particularly …

This article is published as part of a supplement sponsored by Kidney Disease: Improving
Global Outcomes (KDIGO). The opinions or views expressed in this supplement are those of …

Rationale & Objective Renin-angiotensin-aldosterone system (RAAS) inhibitors are
evidence-based therapies that slow the progression of chronic kidney disease (CKD) but …